The population is aging, triggering a “silver tsunami” of neurodegenerative diseases, especially Alzheimer’s and Parkinson. At the same time, precision medicine holds tremendous promise for many CNS disorders, including age-related neurodegenerative ones.
Researchers today better understand the heritability of neurological and psychiatric disease, although there is still so much more to learn. Through advances in genetics and genomics, they are making tremendous progress in identifying the genes and gene variants involved in neurodegeneration. As a result, genetic testing is making it easier to identify patients for clinical trials.
However, genetic testing in the context of clinical trials raises important ethical issues, including ones related to informed consent and disclosure of results. As is often the case with technology, the science may be outpacing our understanding of the broader implications. In fact, such concerns have spawned a relatively new field of study—neurogenethics. In addition, myriad operational concerns exist for sponsors and sites; they range from finding patients to test and identifying which genes and mutations to test for, to designing appropriate protocols and managing the resulting data and results.
Genetic counselors can play a crucial role in helping sponsors address these operational and ethical issues, making trials more efficient, more patient-centered and, ultimately, more successful.
Access the whitepaper to learn more.
About the Authors
Jill Johnston is the President, Site Support and Management for WCG Clinical Services.
Tricia See, ScM, GCG, is the Cardiac and Neurogenetics Team Lead at InformedDNA